MX2020004666A - Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. - Google Patents

Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.

Info

Publication number
MX2020004666A
MX2020004666A MX2020004666A MX2020004666A MX2020004666A MX 2020004666 A MX2020004666 A MX 2020004666A MX 2020004666 A MX2020004666 A MX 2020004666A MX 2020004666 A MX2020004666 A MX 2020004666A MX 2020004666 A MX2020004666 A MX 2020004666A
Authority
MX
Mexico
Prior art keywords
treatment
lipoic acid
ocular disorders
pilocarpine
compounds
Prior art date
Application number
MX2020004666A
Other languages
English (en)
Other versions
MX389626B (es
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2020004666A publication Critical patent/MX2020004666A/es
Publication of MX389626B publication Critical patent/MX389626B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aspectos de la presente divulgación proveen el compuesto de Fórmula I e hidratos, solvatos, cristales, co-cristales, enantiómeros, estereoisómeros, polimorfos y profármacos farmacéuticamenteaceptables de los mismos que pueden encontrar utilidad en el tratamiento de trastornos oculares y complicaciones asociadas con los mismos. Aspectos de la presente divulgación se relacionan con métodos para tratar un trastorno ocular y/o complicaciones del mismo en un sujeto en necesidad del mismo mediante la administración del compuesto de Fórmula I o un hidrato, solvato, cristal, enantiómero, estereoisómero, polimorfo y profármaco farmacéuticamente aceptables de los mismos. (Ver fórmula I) en donde, X+ representa, (Ver fórmula).
MX2020004666A 2017-11-17 2018-09-22 Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. MX389626B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741041231 2017-11-17
PCT/IB2018/057342 WO2019097318A1 (en) 2017-11-17 2018-09-22 Compositions and methods for the treatment of eye disorders

Publications (2)

Publication Number Publication Date
MX2020004666A true MX2020004666A (es) 2022-01-26
MX389626B MX389626B (es) 2025-03-20

Family

ID=66540065

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004666A MX389626B (es) 2017-11-17 2018-09-22 Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.

Country Status (14)

Country Link
US (1) US10933052B2 (es)
EP (1) EP3651747A4 (es)
JP (1) JP7006990B2 (es)
KR (1) KR102349776B1 (es)
CN (1) CN111372576A (es)
AU (1) AU2018367909B2 (es)
BR (1) BR112020009361A2 (es)
CA (1) CA3081553C (es)
IL (1) IL274234B2 (es)
MX (1) MX389626B (es)
RU (1) RU2761436C1 (es)
SG (1) SG11202004019SA (es)
WO (1) WO2019097318A1 (es)
ZA (1) ZA202002066B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL265791B (en) * 2016-10-04 2022-07-01 Cellix Bio Private Ltd Compositions and methods for the treatment of xerostomia
EP3709982A4 (en) * 2017-11-17 2021-10-13 Cellix Bio Private Limited COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISEASES AND SKIN DISEASES
EP3749303A4 (en) * 2018-02-05 2022-01-26 Cellixbio Private Limited COMBINATION OF AN ANTIMUSCARINE OR ANTICCHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF
MX2022006803A (es) 2019-12-04 2022-09-19 Restore Vision Llc Formulaciones oftalmicas para el tratamiento de la presbicia.
US11400039B2 (en) * 2020-01-16 2022-08-02 James W. Hill Changing eye color by gene transduction
IL298476A (en) * 2020-05-26 2023-01-01 Cellix Bio Private Ltd Pharmaceutical formulations of pilocarpine r-(+)-lipoate
WO2023052974A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Ocular compositions and methods for the treatment of ophthalmic diseases and disorders
WO2024108202A2 (en) * 2022-11-19 2024-05-23 Iview Therapeutics, Inc. Compounds, compositions and methods for treatment of age-related ocular disorders
WO2025230326A1 (ko) * 2024-04-30 2025-11-06 주식회사태준제약 필로카르핀을 포함하는 점안 조성물

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50250A (en) 1975-08-27 1980-01-31 Hydrophilics Int Inc Sustained release compositions comprising slats of pharmaceutically acitve bases with polymers containing acid groups
US4076942A (en) 1975-10-01 1978-02-28 Merck & Co., Inc. Crystalline dipilocarpinium pamoate
FR2424930A1 (fr) 1978-05-02 1979-11-30 Inst Khim Drevesiny Akadem Nouveaux polymeres d'alcoyl-1(oxo-5 alcoyl-4 tetrahydrofuryl-methyl(3)-5) imidazoles et d'ethers carboxyalcoyliques d'alcool polyvinylique, utiles notamment comme agents m-cholinomimetiques et leur procede de preparation
US4977176A (en) 1987-01-31 1990-12-11 Sandoz Ltd. Pilocarpine compounds which are used as pharmaceutical agents
NL8800099A (nl) 1987-01-31 1988-08-16 Sandoz Ag Pilocarpinederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
JP2771257B2 (ja) 1989-06-22 1998-07-02 岩城製薬株式会社 イミダゾール誘導体の製法
US5322942A (en) 1991-06-03 1994-06-21 Regents Of The University Of California Synthesis of optically active lactones from L-aspartic acid and intermediates thereof
DE4222459C2 (de) 1992-07-08 1995-09-14 Sigma Tau Ind Farmaceuti 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
DE4334135A1 (de) 1993-10-07 1995-04-13 Merck Patent Gmbh Verfahren zur Herstellung von Pilocarpin-Derivaten
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
JPH11512399A (ja) 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法
US5811428A (en) 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
EP1170009B1 (en) 1996-01-22 2004-04-07 Fujisawa Pharmaceutical Co., Ltd. Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
US6222039B1 (en) 1998-07-13 2001-04-24 Hoffman-La Roche Inc. Process for the preparation of chiral lactones
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
TWI283669B (en) 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
WO2002098877A1 (en) 2001-06-05 2002-12-12 Lilly Icos Llc Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
CA2499601A1 (en) 2002-09-19 2004-04-01 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
DE10358539A1 (de) 2003-12-15 2005-07-07 Merck Patent Gmbh Carbonsäureamidderivate
US7601840B2 (en) 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
CN101522658A (zh) 2006-06-16 2009-09-02 因迪基恩药物公司 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
WO2009105782A1 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Hiv protease inhibitor and cytochrome p450 inhibitor combinations
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20110124626A1 (en) 2008-07-18 2011-05-26 Takeda Pharmaceutical Company Limited Benzazepine derivatives and their use as histamine h3 antagonists
US20110091459A1 (en) 2008-12-11 2011-04-21 Auspex Pharmaceuticals, Inc. Imidazole modulators of muscarinic acetylcholine receptor m3
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
SI3708178T1 (sl) * 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
WO2011113060A2 (en) 2010-03-12 2011-09-15 Trana Discovery, Inc. Antiviral compounds and methods of use thereof
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
RU2013129818A (ru) 2010-11-30 2015-01-10 Дженентек, Инк. Способы анализа и биомаркеры для гена lrrk2
WO2012079032A2 (en) 2010-12-09 2012-06-14 Trana Discovery, Inc. Compositions and methods of treating drug-resistant retroviral infections
CA2831710A1 (en) 2011-03-31 2012-10-04 Bayer Intellectual Property Gmbh Substituted benzimidazoles as mps-1 kinase inhibitors
US20140255392A1 (en) 2011-04-06 2014-09-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
JP2012230356A (ja) 2011-04-15 2012-11-22 Sumitomo Chemical Co Ltd 化合物、レジスト組成物及びレジストパターンの製造方法
GB201114448D0 (en) 2011-08-22 2011-10-05 Takeda Pharmaceutical Compounds and their use
US20140228384A1 (en) 2011-11-29 2014-08-14 Genentech, Inc. Assays and biomarkers for lrrk2
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
CN104080773B (zh) 2012-01-28 2016-12-28 默克专利股份公司 氮杂环化合物
WO2013144191A1 (de) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US8853259B2 (en) * 2013-02-07 2014-10-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications
EP3030555B1 (en) 2013-08-08 2019-01-30 Boehringer Ingelheim International GmbH Novel pyrazine amide compounds
WO2015082378A1 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2015082376A2 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US20160317606A1 (en) 2014-01-06 2016-11-03 Stealth Bio Therapeutics Corp Methods and compositions for preventing or treating dominant optic atrophy
US9365520B2 (en) 2014-07-01 2016-06-14 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN104387364B (zh) 2014-12-15 2016-11-16 南京工业大学 L-鸟氨酸硫辛酸复合盐及其制备方法和应用
IL265791B (en) * 2016-10-04 2022-07-01 Cellix Bio Private Ltd Compositions and methods for the treatment of xerostomia

Also Published As

Publication number Publication date
US10933052B2 (en) 2021-03-02
WO2019097318A1 (en) 2019-05-23
IL274234A (en) 2020-06-30
CA3081553A1 (en) 2019-05-23
NZ763688A (en) 2021-10-29
MX389626B (es) 2025-03-20
ZA202002066B (en) 2021-07-28
EP3651747A1 (en) 2020-05-20
EP3651747A4 (en) 2020-07-22
RU2761436C1 (ru) 2021-12-08
IL274234B (en) 2022-10-01
KR102349776B1 (ko) 2022-01-10
CN111372576A (zh) 2020-07-03
JP2021503449A (ja) 2021-02-12
BR112020009361A2 (pt) 2020-10-13
KR20200089292A (ko) 2020-07-24
AU2018367909B2 (en) 2022-03-10
US20200179343A1 (en) 2020-06-11
JP7006990B2 (ja) 2022-02-10
IL274234B2 (en) 2023-02-01
AU2018367909A1 (en) 2020-05-07
CA3081553C (en) 2022-11-15
SG11202004019SA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
EP3383447A4 (en) LIGHT-ACTIVATED HYDROGEL PRODUCTION
HUE063868T2 (hu) Ortokeratológiai kontaktlencse miópia kezelésére
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CR20180374A (es) Compuestos heterocíclicos como inmunomoduladores
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
UY36629A (es) Indazolonas como moduladores de la señalización de tnf
EA201790785A1 (ru) Производные тетрагидроизохинолина
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
CU20170037A7 (es) Compuestos derivados de n-alquilaril-5-oxiaril-octahidro ciclopenta[c)pirrol moduladores alostéricos negativos de nr2b
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
LT3805220T (lt) Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
UY36630A (es) Moduladores tricíclicos de la señalización por tnf
EA201990400A1 (ru) Соединения и композиции и их применение
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
CL2019002583A1 (es) Inhibidores duales de magl y faah.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
EA201790893A1 (ru) Способы лечения офтальмологических расстройств